Safety and Effectiveness of Inhaling Different Dosage Recombinant Human Interferon <i>α</i>1B for Bronchiolitis in Children: a Systematic Review and Meta-Analysis

Luo, Jiefeng; Yang, Mengting; Zeng, Linan; Pan, Xiangcheng; Liu, Dan; Diao, Sha; Huang, Liang; Chen, Ting; Jia, Zhi-Jun; Cheng, Guo; Yu, Qin; Zhang, Lingli

doi:https://doi.org/10.1155/2022/2229735

Evidence-Based Complementary and Alternative Medicine

On this page

Abstract Introduction Methods Results Limitations Conclusions Data Availability Conflicts of Interest Acknowledgments Supplementary Materials References Copyright Related Articles

Research Article | Open Access

Volume 2022 | Article ID 2229735 | https://doi.org/10.1155/2022/2229735

Safety and Effectiveness of Inhaling Different Dosage Recombinant Human Interferon α1B for Bronchiolitis in Children: a Systematic Review and Meta-Analysis

Jiefeng Luo,^1,2,3,4Mengting Yang,^2,3,4,5Linan Zeng,^2,3,4Xiangcheng Pan,^1,2,3,4Dan Liu,^1,2,3,4Sha Diao,^2,3,4Liang Huang,^2,3,4Ting Chen,⁶Zhi-Jun Jia,^1,2,3,4Guo Cheng,^4,6,7Qin Yu,^4,8and Lingli Zhang^2,3,4

Academic Editor: Roberto Miniero

Received10 Jan 2022

Revised30 Mar 2022

Accepted04 Apr 2022

Published27 Apr 2022

Abstract

Purpose. To systematically evaluate the safety and effectiveness of different dosages of recombinant human interferon α1b (IFNα1b) inhaled for bronchiolitis in children. Methods. 7 databases, including PubMed, EMBASE, Cochrane Library, Web of Science, CNKI, Wanfang Database, and VIP, were searched. The search time was from their inception dates to March 28, 2022. A randomized controlled trial (RCT) of 2 μg/kg IFNα1b (low dosage group) monotherapy or in combination with other drugs vs. 4 μg/kg IFNα1b (high dosage group) monotherapy or in combination with the other drugs was included. The risk of bias 2.0 evaluated the RCT’s quality, and the grading of recommendations assessment, development and evaluation (GRADE) tool was used for evaluating the overall quality of the evidence. Then, a meta-analysis was performed by RevMan 5.4. Results. A total of 13 RCTs with 1719 children were included. The meta-analysis results showed that the high dosage group was significantly shorter than the low dosage group of the duration of hospital stays (MD = −0.40, 95%CI (−0.73, −0.07), = 0.02) (low quality), three depressions sign disappearing time (MD = −0.60, 95%CI (−1.05, −0.14), = 0.010) (low quality), and wheeze disappearing time (MD = −0.62, 95%CI (−1.17, −0.06), = 0.03) (low quality). There was no significant difference between the two groups in coughing disappearing time, pulmonary rales disappearing time, wheezing sound disappearing time, or adverse event rates. Conclusions. Compared with low dosage IFNα1b, high dosage IFNα1b reduces the duration of hospital stays, the disappearance time of the three depression signs, and the disappearance time of wheeze in the treatment of bronchiolitis in children. Limited by the low quality of the evidence, the conclusions still need to be supported by high-quality studies.

1. Introduction

Bronchiolitis is a lower respiratory tract disease that mainly occurs in children under 24 months. The peak age of onset ranges from 2 months to 6 months. The incidence of infants in the first year after birth is approximately 11%, and bronchiolitis is one of the leading causes of illness and hospitalization in children under one year old [1, 2]. The most common etiology of bronchiolitis is respiratory syncytial virus (RSV) infection. Other viruses include the parainfluenza virus, influenza virus, and rhinovirus [2, 3]. Unfortunately, a causative treatment of acute viral bronchiolitis does not exist due to its special pathophysiology [4, 5]. In clinical practice, oxygen and fluid supplementation are usually used for symptomatic treatment [6].

Interferon (IFN) plays an essential role during bronchiolitis, particularly for children infected with RSV [7]. IFNs are a group of signaling proteins synthesized and released by host cells in response to pathogens. Normally, virus-infected cells release IFNs to enable surrounding cells to improve their anti-viral defenses [8]. This early response can influence the clinical course of RSV bronchiolitis, thereby affecting the duration of the disease and damage to the lungs [9]. However, it has been considered that common respiratory viruses, including RSV, may disrupt the host antiviral IFN response [9–12]. Based on the importance of IFN in bronchiolitis, many researchers in China have used exogenous IFN as a supplementary treatment for bronchiolitis.

Recombinant human interferon α1B (IFNα1B), as a major antiviral subtype in the Chinese population, has attracted the attention of Chinese researchers [5]. As the lesion site of bronchiolitis is located in the bronchioles, administration by nebulized has the advantages of rapid-onset, fewer adverse reactions, and high compliance [5]. Therefore, aerosol inhalation IFNα1B for bronchiolitis in children has been recommended by the Chinese National Formulary [13] and the Standardized Management Guidelines for Children’s Nebulization Center [14]. At present, the guidelines or expert consensus recommended dosage of nebulized IFNα1b for bronchiolitis in children is 2–4 μg/kg [15, 16]. However, there is still controversy about 2 μg/kg or 4 μg/kg in clinical practice. Some researchers believe that 4 μg/kg of IFNα1b has better efficacy [17, 18]. Others believe that 2 μg/kg and 4 μg/kg of IFNα1b have equivalent efficacy. Considering the safety and economic effects, 2 μg/kg IFNα1b should be promoted [19, 20].

Therefore, this study aims to evaluate the safety and effectiveness of inhaling 2 μg/kg and 4 μg/kg of IFNα1b for bronchiolitis in children, providing evidence-based evidence for clinical practice.

2. Methods

This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [21].

2.1. Search Strategy

A total of 7 databases, including PubMed, Embase (Ovid), Cochrane Library (Ovid), Web of Science, CNKI, Wanfang Database, and VIP, were searched. Additionally, we used a manual search strategy to retrieve the relevant articles cited by the retrieved publications. The search time was from their inception dates to March 28, 2022. Medical subject headings combined with free text terms were used to search for eligible articles. Two clinical trial registration sites, including clinicaltrials.gov (https://clinicaltrials.gov/) and the WHO International Clinical Trials Registry Platform (ICTRP) (http://apps.who.int/trialsearch/), were searched for unpublished but eligible articles.

2.2. Inclusion and Exclusion Criteria

2.2.1. The Inclusion Criteria

Population: infants under 2 years old and hospitalized with a diagnosis of bronchiolitis.

Intervention/control: the high dosage group was given 4 μg/kg IFNα1b, and the low dosage group was given 2 μg/kg IFNα1b, and both were treated with nebulization. IFNα1b monotherapy or in combination with other drugs (e.g., budesonide, albuterol, and hypertonic saline) were included.

Outcomes: the primary outcome is the duration of hospital stays. The secondary outcome is based on the main clinical symptoms described in the “Expert consensus on the diagnosis, treatment and prevention of bronchiolitis (2014),” including cough disappearance time, pulmonary rales disappearance time, wheeze disappearance time, and wheezing sound disappearance time, three depression sign disappearance times, and adverse event rates.

2.2.2. The Exclusion Criteria

(1)Non-Chinese and Non-English studies(2)Inaccessible studies(3)No information about the child(4)Duplicate publication

2.3. Data Extraction and Risk-of-Bias Assessments

Two researchers selected the included RCTs back-to-back according to the inclusion and exclusion criteria and extracted the data. Cochrane risk of bias assessment tool (ROB 2.0) was used to evaluate the RCT’s quality, and the grading of recommendations assessment, development and evaluation (GRADE) tool was used to evaluate the overall quality of evidence. When two researchers had opposite opinions, disputes were decided by the third researcher. The content of the literature extraction includes basic information about the literature (such as first author and year of publication); basic information about the child (such as age and course of the disease); basic information about intervention (such as course of treatment, frequency of administration, and combined therapy); and research results (data of outcomes).

2.4. Statistical Analysis

RevMan 5.4 statistical software provided by the Cochrane Collaboration Network was performed for meta-analysis. Relative risk (RR) and risk difference (RD) were used for dichotomous data, mean difference (MD) was used for continuous data, and 95% CIs were calculated using the Mantel–Haenszel method and the inverse variance statistical method, respectively. Heterogeneity was tested by χ² test and I² statistics, and the random effect model was performed for meta-analysis. Subgroup analysis was performed by monotherapy or combined therapy. Sensitivity analysis was performed by eliminating included RCTs one by one in each outcome.

3. Results

The initial searches included 2129 RCTs. After deduplication, 927 RCTs were removed. After screening titles and abstracts, 1013 RCTs were removed. Ultimately, 13 RCTs remained after screening full texts [17–20, 22–30] (Figure 1).

3.1. Characteristics of the Included Studies

The basic information of the included RCT is presented in Table 1. Among the included RCTs, 5 RCTs adopted a random number table for randomization [17, 24, 26–28], 1 RCT adopted the envelope method for randomization [18], and the rest did not describe the method or used the wrong method. 1 RCT adopted a central randomization system for concealed allocation [17], and the rest did not mention the method for concealed allocation. Only 1 RCT risk-of-bias assessment result was “Some concerns” [17], and the results of the other RCTs were “High risk”(Figures 2 and 3); GRADE results were “low” and “very low” (Table 2).

Chen 2018 [18] subdivided the drug administration into the early high dosage group, the early low dosage group, the late high dosage group, and the late low dosage group. Since there were no overlap children between early and late, the early and late were independently analyzed. Additionally, Zhao 2018 [17] subdivided the low dosage group into the qid group and the tid group. Since there were no overlap children between the qid group and the tid group, the qid group and the tid group were combined into the low dosage group.

3.2. Primary Outcome

The duration of hospital stays: 8 RCTs included 733 children [18–20, 22, 23, 26, 27, 29]. The duration of hospital stays in the high dosage group was significantly shorter than that in the low dosage group (MD = −0.40, 95%CI (−0.73,−0.07), = 0.02; I² = 68%) (low quality) (Figure 4).

3.3. Secondary Outcomes

Three depression signs disappearing time: 4 RCTs included 487 children [17, 18, 22, 28]. Three depressions sign disappearing time in the high dosage group was significantly shorter than that in the low dosage group (MD = −0.60, 95%CI (−1.05,−0.14), P = 0.010; I² = 75%) (low quality) (Figure 5).

Cough disappearance time: 8 RCTs included 797 children [17–19, 23, 27–30]. There was no significant difference in coughing disappearance time between the high dosage group and the low dosage group (MD = −0.13, 95%CI (−0.43, 0.16), = 0.38; I2 = 63%) (very low quality) (Figure 6).

Pulmonary rales disappearing time: 4 RCTs included 303 children [18, 22, 25, 29]. There was no significant difference in pulmonary rales disappearance time between the high dosage group and the low dosage group (MD = −0.25, 95%CI (−0.94, 0.43), = 0.47; I2 = 83%) (very low quality) (Figure 7).

Wheeze disappearing time: 3 RCTs included 381 children [17, 18, 28]. Wheeze disappearing time in the high dosage group was significantly shorter than that in the low dosage group (MD = −0.62, 95%CI (−1.17,−0.06), = 0.03; I² = 73%) (low quality) (Figure 8).

Wheezing sound disappearing time: 3 RCTs included 179 children. The high dosage group and the low dosage group had no significant difference in wheezing sound disappearance time (MD = 0.01, 95%CI (−0.37, 0.39), = 0.96; I2 = 0%) (low quality) (Figure 9).

Adverse event rates: 13 RCTs included 1251 children [17–20, 22–30]. The high dosage group and the low dosage group had no significant difference in adverse event rates (RR = 1.20, 95%CI (0.61, 2.39), = 0.59; RD = 0.00, 95%CI (−0.01, 0.02), = 0.77; I2 = 0%) (low quality) (Figures 10 and 11).

3.4. Subgroup Analysis

3.4.1. The Duration of Hospital Stays

The results of subgroup analysis showed that when IFNα1b was combined with other drugs, the hospital stay in the high dosage group was significantly shorter than that in the low dosage group (MD = −0.44, 95%CI (−0.84, −0.03), = 0.04; I² = 71%); when IFNα1b was treated with monotherapy, there was no statistically significant difference in hospital stay between the two groups (MD = −0.21, 95%CI (−0.51, 0.09), = 0.17) (Figure 12).

3.4.2. Adverse Event Rates

The results of subgroup analysis showed that regardless of IFNα1b combined therapy or monotherapy, there was no statistically significant difference in adverse event rates between the two groups (Figures 13 and 14).

3.5. Sensitivity Analysis

When eliminating Li 2019, the heterogeneity of the duration of hospital stays, cough disappearance time, and wheeze disappearance time decreased significantly. The meta-analysis results of the duration of hospital stays, cough disappearance time, three depression sign disappearance times, wheezing sound disappearance times, and adverse event rates showed no change after eliminating including RCTs one by one. The meta-analysis results of pulmonary rales disappearing time turned into statistically significant differences (MD = −0.55, 95%CI (−1.06,−0.04)) when eliminating Zhao 2018. The meta-analysis results of wheeze disappearing time turned into no statistically significant difference (MD = −0.38, 95%CI (−0.87, 0.11)) when eliminating Li 2019.

4. Discussions

4.1. Summary

Bronchiolitis is a lower respiratory tract infection mainly involving small airways (bronchioles). It is a common cause of illness and hospitalization in infants and young children. Severe bronchiolitis may also increase the risk of children developing asthma and continue to adulthood [6, 31, 32]. Therefore, the etiological treatment of bronchiolitis is of great importance.

This study included 13 RCTs with 1719 children to study the safety and effectiveness of different dosages of IFNα1b inhalation for bronchiolitis. The results showed that in the duration of hospital stays, wheeze disappearing time, and three depressions sign disappearing time, the high-dosage group is significantly shorter than the low-dosage group ( ≤ 0.05), but there was no difference between the two groups in cough disappearance time, pulmonary rales disappearing time, wheezing sound disappearing time, and adverse event rates ( > 0.05).

4.2. Comparison with Similar Research

Chen Can [33] conducted a meta-analysis on the effectiveness and safety of IFNα1b nebulized inhalation for bronchiolitis based on 24 RCTs. The study results concluded that IFNα1b nebulized inhalation is safe and effective for bronchiolitis. However, there are still some problems in this study. The first is the high heterogeneity, such as the outcome of the duration of hospital stays (＜0.01, I² = 98%), and the subgroup analysis of different doses of IFNα1b did not reduce the heterogeneity. In addition, only 3 RCTs compared different dosages of IFNα1b [17, 19, 30], and different dosages of IFNα1b were not further studied.

4.3. Sensitivity Analysis

When eliminating Li 2019 [18], the heterogeneity of each outcome has decreased, and the meta-analysis results of wheeze disappearance time have changed. The possible reason is that the disease course of children in this RCT (both groups are ＜24 hours) is significantly shorter than in other RCTs (1–6 days). Another cause may be that the children have a high proportion of fever. The proportion of children with a temperature ≥39°C in the high and low dosage groups is 30% and 43%, respectively. However, the consensus points out that the temperature of children with bronchiolitis generally does not exceed 39°C [3]. When eliminating Zhao (2018), the meta-analysis results of pulmonary rales disappearing time have changed. The possible reason is that Zhao (2018) [25] subdivides the low dosage group into three times a day and two times a day. However, it is unified into the low dosage group for statistical analysis in this study, which may lead to a change in baseline comparability. The difference in sample size between the high dosage group and the low dosage group may also be one of the reasons.

4.4. Subgroup Analysis

Subgroup analysis showed no significant difference between the high dosage group and the low dosage group in the duration of hospital stays and adverse event rates when IFNα1b was treated with monotherapy. In terms of the duration of hospital stays, the conclusions of monotherapy and when combined with other drugs are inconsistent. However, considering that there is only 1 RCT on monotherapy, it cannot be concluded that there is no statistically significant difference in the duration of hospital stays between the high dosage group and the low dosage group when IFNα1b was treated with monotherapy. A large sample, multicenter clinical research is needed to support these results.

4.5. Risk-of-Bias Assessments

The areas of lower quality are “Randomization process” and “Randomization process,” 53.85% of the RCTs did not use or used the wrong method for randomization, such as according to the order of admission, which may lead to incomparable baselines between the two groups. In addition, 92.31% of the RCTs did not use blinding or concealed allocation, which may lead to bias when giving interventions or measuring outcome data.

5. Advantages and Limitations

5.1. Advantage

There has been controversy about the different dosages of IFNα1b inhaling for bronchiolitis in clinical practice. However, there is not any evidence-based medical evidence. This study uses systematic reviews and meta-analysis methods to provide a reference for clinical practice.

5.2. Limitation

There are some limitations to this study. First, the quality of the included RCTs is low. Only 1 RCT has a result of “Some concerns,” and the others are “High risk.” Second, most of the outcomes of this study adopt the disappearance time of disease symptoms, and the judgment criteria are subjective. Third, since none of the included RCTs mentioned the symptom classification of bronchiolitis, the disease severity was not considered in this study.

6. Conclusions

Compared with the low dosage IFNα1b, the high dosage IFNα1b reduces the duration of hospital stays, the disappearance time of the three depression signs, and the disappearance time of wheeze in the treatment of bronchiolitis in children. Limited by the quality of the included RCTs, the above conclusions still need to be supported by large samples and high-quality studies.

Data Availability

The RevMan data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The author reports no conflicts of interest in this work.

Acknowledgments

This study was supported by the Sichuan Province Science and Technology Plan Project (No.2020YFS0035) and Subproject of Science and Technology Plan Project of Sichuan Province (20ZDYF3101).

Supplementary Materials

Search strategies for all databases can be seen in the supplementary material. (Supplementary Materials)

References

Merck Clinic Manual[homepage on the Internet]. Bronchiolitis. 2018-08-01; https://www.msdmanuals.cn/professional/pediatrics/respiratory-disorders-in-young-children/bronchiolitis.
T. A. Florin, A. C. Plint, and J. J. Zorc, “Viral bronchiolitis,” The Lancet, vol. 389, no. 10065, pp. 211–224, 2017.
View at: Publisher Site | Google Scholar
E. Liu, H. Chen, and Y. Qian, “Expert consensus on the diagnosis, treatment and prevention of bronchiolitis (2014),” Chin J Pediatr, vol. 53, no. 03, pp. 168–171, 2015.
View at: Google Scholar
J. Meyburg and M. Ries, “Decision-making in acute viral bronchiolitis: a universal guideline and a publication gap,” PLoS One, vol. 15, no. 8, p. e0237801, 2020.
View at: Publisher Site | Google Scholar
L. Chen, M. Shi, and Q. Deng, “αA multi-center randomized prospective study on the treatment of infant bronchiolitis with interferon α1b nebulization,” PLoS One, vol. 15, no. 2, p. e0228391, 2020.
View at: Publisher Site | Google Scholar
H. C. Meissner, “Viral bronchiolitis in children,” New England Journal of Medicine, vol. 374, no. 1, pp. 62–72, 2016.
View at: Publisher Site | Google Scholar
D. A. Paggi and F. P. Polack, “Toward personalized medicine in bronchiolitis,” American Journal of Respiratory and Critical Care Medicine, vol. 199, no. 12, pp. 1456–1458, 2019.
View at: Publisher Site | Google Scholar
L. Rönnblom, “The importance of the type I interferon system in autoimmunity,” Clinical & Experimental Rheumatology, vol. 34, no. 4 Suppl 98, pp. 21–24, 2016.
View at: Google Scholar
F. Savino, V. Daprà, A. Savino, and C. P. I. M. Calvi, “Assessment of interferon gamma and indoleamine 2,3-dioxygenase 1 analysis during respiratory syncytial virus infection in infants in Italy: an observational case-control study,” BMJ Open, vol. 12, no. 2, p. e053323, 2022.
View at: Publisher Site | Google Scholar
R. S. Thwaites, M. Coates, K. Ito, and M. C. F. T. P. L. G. T. T. S. P. Ghazaly, “Reduced nasal viral load and IFN responses in infants with respiratory syncytial virus bronchiolitis and respiratory failure,” American Journal of Respiratory and Critical Care Medicine, vol. 198, no. 8, pp. 1074–1084, 2018.
View at: Publisher Site | Google Scholar
J. Ban, N.-R. Lee, N.-J. Lee, J. K. Lee, F.-S. Quan, and K.-S. Inn, “Human respiratory syncytial virus NS 1 targets TRIM25 to suppress RIG-I ubiquitination and subsequent RIG-I-mediated antiviral signaling,” Viruses, vol. 10, no. 12, p. 716, 2018.
View at: Publisher Site | Google Scholar
T. Van Royen, I. Rossey, K. Sedeyn, B. Schepens, and X. Saelens, “How RSV proteins join forces to overcome the host innate immune response,” Viruses, vol. 14, no. 2, p. 419, 2022.
View at: Publisher Site | Google Scholar
Chinese National Formulary, Chinese National Formulary: Chemicals and Biological Products Volume, People’s Military Medical Publishing House, Beijing, China, 2013.
K. Shen, J. Hong, and G. Yu, Guidelines for Standardized Management of Children’s Nebulization Center, People’s Medical Publishing House, Beijing, China, 2014.
K. Shen, Y. Shang, and G. Zhang, “Expert consensus on the rational application of interferon alpha in pediatrics,” Chinese Journal of Applied Clinical Pediatrics, vol. 33, no. 17, pp. 1301–1308, 2018.
View at: Google Scholar
K. Shen, G. Zhang, and Y. Shang, “Expert consensus on the clinical application of recombinant human interferon-α1b in pediatrics,” Chinese Journal of Applied Clinical Pediatrics, vol. 30, no. 16, pp. 1214–1219, 2015.
View at: Google Scholar
Y. Shang, Y. Huang, and E. Liu, “A multicenter clinical study on the treatment for children’s acute bronchiolitis by nebulized recombinant human interferon α 1b,” Chinese Journal of Practical Pediatrics, vol. 29, no. 11, pp. 840–844, 2014.
View at: Google Scholar
X. Li, Z. Ye, and Y. Hu, “The effect of aerosol inhalation of recombinant human interferon α1b on the immune function of children with bronchiolitis,” Maternal and Child Health Care of China January, vol. 34, no. 02, pp. 345–348, 2019.
View at: Google Scholar
Y. Huang, “Effect and safety of interferon α1b treatment of bronchiolitis in children,” Journal of Pediatric Pharmacy, vol. 21, no. 08, pp. 25–27, 2015.
View at: Google Scholar
W. Yinan, “Observation on the effect of different doses of recombinant human interferon α1b nebulized inhalation on bronchiolitis,” Medical Frontier, vol. 8, no. 31, pp. 98-99, 2018.
View at: Google Scholar
D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” BMJ, vol. 339, no. jul21 1, p. b2535, 2009.
View at: Publisher Site | Google Scholar
L. Cai, “Clinical comparison of different doses of recombinant human interferon 1B aerosolized treatment of bronchiolitis in children,” Contemporary Medical Symposium, vol. 18, no. 13, pp. 125–127, 2020.
View at: Google Scholar
Y. Liu, “Effect of nebulized inhalation of different doses of recombinant human interferon α1b on acute bronchiolitis in children,” Contemporary Clinical Medicine Journal, vol. 32, no. 01, pp. 62-63, 2019.
View at: Google Scholar
R. Dai, “Comparison of different doses of recombinant human interferon α1b in the treatment of acute bronchiolitis in children,” Journal of North Pharmacy, vol. 16, no. 05, p. 179+178, 2019.
View at: Google Scholar
M. Zhao, H. Jin, and W. Lin, “Observation on the curative effect of nebulized inhalation of different doses of interferon-α1b in the treatment of bronchiolitis,” Home medicine, vol. 6, pp. 150-151, 2018.
View at: Google Scholar
C. Chen, Li Jian, Yu Zhang, X. Chen, Y. Fan, and S. Wang, “Effects of early inhalation of recombinant human interferon α1b on children’s bronchiolitis,” Journal of Xuzhou Medical University, vol. 38, no. 5, pp. 337–343, 2018.
View at: Google Scholar
J. Xu, X. Zhou, and Q. Deng, “Comparison of different doses of recombinant human interferon α1b in treatment of acute bronchiolitis in children,” Hainan Medical Journal, vol. 28, no. 13, pp. 2116–2118, 2017.
View at: Google Scholar
L. Xing, H. Liu, Q. Zheng, Y. Zhou, J. Zhang, and W. Chen, “Study on nebulization of interferon and ribavirin in the treatment of bronchiolitis,” Strait Journal of Preventive Medicine, vol. 23, no. 03, pp. 97–99, 2017.
View at: Google Scholar
C. Zhanhu, H. Yan, L. Qin, H. Yan, and L. Qin, “Clinical analysis of nebulized inhalation of different doses of recombinant human interferon α-1b in the treatment for Bronchiolitis in Infants,” Medical Frontier, vol. 6, pp. 121-122, 2016.
View at: Google Scholar
T. Hu, J. Guo, and J. Yu, “Study on the clinical efficacy of different doses of recombinant human interferon α1b nebulized inhalation in the treatment of bronchiolitis,” For all Health, vol. 8, no. 01, pp. 227-228, 2014.
View at: Google Scholar
N. Yang and S. Yunxiao, “The relationship between bronchiolitis and asthma,” Chin J Pediatr, vol. 34, no. 09, pp. 737–742, 2019.
View at: Google Scholar
G. Wang, D. Han, Z. Jiang, M. Li, S. Yang, and L. Liu, “Association between early bronchiolitis and the development of childhood asthma: a meta-analysis,” BMJ Open, vol. 11, no. 5, p. e043956, 2021.
View at: Publisher Site | Google Scholar
C. Chen, M. Liping, Z. Lei, S. Sijing, and Z. Suodi, “Efficacy and safety of recombinant human interferon α1b injection inhaling as adjuvant therapy for bronchiolitis in infants: a systematic review and meta-analysis,” Evaluation and analysis of drug-use in hospitals of China, vol. 16, no. 06, pp. 806–810, 2016.
View at: Google Scholar

Copyright

Copyright © 2022 Jiefeng Luo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies